Michael R. Megna Sells 17,000 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock

Key Points

• Michael R. Megna, CAO of Kiniksa Pharmaceuticals, sold 17,000 shares at an average price of $32.35, totaling approximately $549,950, reducing his holdings by nearly 34% to 33,041 shares.
• Kiniksa Pharmaceuticals reported earnings of $0.23 per share, exceeding analysts' expectations, and generated $156.80 million in revenue for the recent quarter.
• Analysts have a favorable outlook on Kiniksa, with several raising target prices and ratings, resulting in an average price target of $41.17 and a consensus rating of "Buy."

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CAO Michael R. Megna sold 17,000 shares of the stock in a transaction on Monday, August 4th. The shares were sold at an average price of $32.35, for a total value of $549,950.00. Following the sale, the chief accounting officer directly owned 33,041 shares in the company, valued at $1,068,876.35. This trade represents a 33.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Kiniksa Pharmaceuticals International Stock Performance

KNSA stock traded down $0.35 during midday trading on Wednesday, reaching $32.72. The stock had a trading volume of 656,035 shares, compared to its average volume of 703,496. The stock has a market cap of $2.39 billion, a PE ratio of 818.20 and a beta of 0.14. The firm has a fifty day simple moving average of $28.63 and a two-hundred day simple moving average of $24.31. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $33.98.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors have recently modified their holdings of the stock. Braidwell LP raised its stake in shares of Kiniksa Pharmaceuticals International by 19.3% during the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company's stock valued at $68,289,000 after buying an additional 557,934 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Kiniksa Pharmaceuticals International by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock valued at $74,606,000 after purchasing an additional 151,604 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 170.3% in the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock valued at $22,961,000 after purchasing an additional 651,700 shares in the last quarter. Millennium Management LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company's stock valued at $18,815,000 after purchasing an additional 67,452 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 7.3% in the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock valued at $15,737,000 after purchasing an additional 54,361 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

Wall Street Analysts Forecast Growth

KNSA has been the topic of several recent research reports. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 9th. Finally, Jefferies Financial Group raised their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.